financetom
Business
financetom
/
Business
/
Scotiabank CEO flags elections in US, Mexico undermining decision making
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Scotiabank CEO flags elections in US, Mexico undermining decision making
Apr 9, 2024 11:01 AM

TORONTO, April 9 (Reuters) - Canadian lender Bank of

Nova Scotia ( BNS ) on Tuesday warned that upcoming elections

in the U.S. and Mexico are creating political uncertainty,

challenging the bank's long-term business decision-making

ability.

Canada's third biggest lender by assets is most exposed to

the North America's booming $1.6 trillion trade and new CEO

Scott Thomson in December unveiled a strategy to benefit from

the regional trade, while potentially exiting or improving

profitability at some weak markets such as Colombia.

"With elections coming this year in Mexico and the United

States, and soon in Canada, there is a level of political

uncertainty that makes it difficult to make the long-term

decisions that will ensure our future prosperity in the region,"

Thomson told investors at the bank's annual meeting.

"But difficult does not mean impossible," he assured

shareholders.

The "Mexico First" strategy offers clients in Canada, the

U.S. and Mexico end-to-end trade finance, Thomson has said, and

is expected to differentiate Scotiabank among its Canadian

rivals.

The plan could expose Scotiabank to a market with

unpredictable political risks and where foreign banks have

struggled to make inroads, analysts have said.

Thomson said North American economic integration could

increase through near-shoring, reducing regulatory hurdles and

ensuring businesses can access capital.

He said the bank's international businesses have improved

with lower capital while it continues to prioritize the three

North American countries which hold a total gross domestic

product of $30 trillion.

Net income from its international banking segment rose 16%

in the first quarter of 2024, making it the strongest growth

segment.

"Our plan is not to get out of those countries. Our plan is

to run them more effectively," Thomson said responding to a

question on the Latin American business.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-QMSK Technology Co Ltd Files For U.S. IPO - SEC FILING
BRIEF-QMSK Technology Co Ltd Files For U.S. IPO - SEC FILING
Jan 28, 2025
Jan 28 (Reuters) - QMSK Technology Co Ltd: * QMSK TECHNOLOGY CO LTD: FILES FOR U.S. IPO * QMSK TECHNOLOGY CO., LTD: EXPECT IPO OFFERING PRICE FOR ORDINARY SHARES WILL BE IN RANGE OF $4.00 TO $6.00 PER SHARE * QMSK TECHNOLOGY CO: EXPECT US IPO PRICE FOR ORDINARY SHARES WILL BE IN RANGE OF $4.00 TO $6.00 PER SHARE...
Tower Semiconductor Analyst Sees 'Attractive' Buying Opportunity Following DeepSeek Selloff
Tower Semiconductor Analyst Sees 'Attractive' Buying Opportunity Following DeepSeek Selloff
Jan 28, 2025
Benchmark analyst Cody Acree named Tower Semiconductor ( TSEM ) Inc. among recommended oversold names following Monday’s market rout, which was triggered by DeepSeek’s announcement of its advanced language model. Monday’s Selloff: Chinese AI lab DeepSeek unveiled a new large language model reportedly meeting or exceeding leading competitors’ performance at a fraction of the cost. The claims, though met with...
Novo Nordisk's Ozempic Gets FDA Approval for Kidney Disease
Novo Nordisk's Ozempic Gets FDA Approval for Kidney Disease
Jan 28, 2025
02:53 PM EST, 01/28/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Tuesday the US Food and Drug Administration approved its Ozempic to reduce the risk of kidney failure, worsening kidney disease and death due to cardiovascular disease in adults with Type 2 diabetes and chronic kidney disease. Price: 86.01, Change: -1.50, Percent Change: -1.71 ...
US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression
US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression
Jan 28, 2025
Jan 28 (Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of chronic kidney disease and the organ's failure, and death due to heart problems in adults with type 2 diabetes. Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same...
Copyright 2023-2026 - www.financetom.com All Rights Reserved